Keeping Axial Spondyloarthritis Patients from Falling Through the Cracks
In this article, we highlight a recent NEJM review that addresses the difference between axial spondyloarthritis and ankylosing spondylitis.
Axial Spondyloarthritis More Common than Previously Thought
Axial spondyloarthritis (SpA) often goes undiagnosed and is more common than previously thought, a study shows.
Diagnosing axSpA and AS in Primary Care
The diagnosis and treatment of spondyloarthritis (axSpA) and ankylosing spondylitis (AS) for primary healthcare providers.
Secukinumab Provides Sustained Improvements in AS
EULAR 2016: Secukinumab prevents radiographic progression in 80 percent of ankylosing spondylitis patients and provides sustained improvements.
AS Infliximab Biosimilar Performs Well in Study
Biosimilar CT-P13 may offer an effective option to infliximab for ankylosing spondylitis.
Secukinumab Approved for Ankylosing Spondylitis and PsA
Approval of secukinumab for ankylosing spondylitis and psoriatic arthritis marks a milestone in rheumatic disease.
New Treatment Guidelines for Ankylosing Spondylitis
The ACR has new treatment guidelines for ankylosing spondylitis, emphasizing strong evidence for treatment with NSAIDs and TNF blockers.
By clicking Accept, you agree to become a member of the UBM Medica Community.